In our investigation of current major cancer problems, we aim to develop highly effective small-molecule drugs against cancers with minimal side-effects and toxicity for humans. We previously developed a series of inhibitors (HKs) from active ingredients of traditional Chinese medicine, targeting the expression of heat-shock proteins (Hsps). In pre-clinical trials these inhibitors were found to block the growth and metastasis of cancers both in vivo and in vitro. In the first stage, we will optimise those inhibitors and register it as an investigational new drug (IND); in the next stage, we will further develop these drugs for clinical trials for treating metastasis of cancers.



Team member(s)

Dr Li Huangcan* (Research Assistant, Dept. of Biomedical Sciences, CityU)
Mr Wang Xiong (PhD, Dept. of Biomedical Sciences, CityU)
Dr Huang Chuan (Alumnus, Dept. of Biomedical Sciences, CityU)

* Person-in-charge
(Info based on the team's application form)


1. CityU HK Tech 300 Seed Fund (2021)